Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Aktis Oncology reported first-in-human imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjugate, showing robust tumor uptake and limited normal tissue exposure in patients with mCRPC and other solid tumors. The data, to be presented at ASCO 2026, demonstrate a favorable therapeutic index with low predicted doses to critical organs like salivary glands compared to approved radiopharmaceuticals, supporting the advancement of Phase 1b trials.
Key figures
- Drug Name
- AKY-2519
- Phase Of Trial
- Phase 1b
- Suv max sclc
- 15.4
- Suv max nsclc
- 17.5-21.5
- Patients mcrpc
- 16
- Suv max rectal
- 15.3
- Suv max prostate
- 33.9-37.4
- Predicted dose liver
- 9.9 Gy
- Patients solid tumors
- 18
- Predicted dose kidneys
- 16 Gy
- Predicted dose bone marrow
- 1.3 Gy
- Predicted dose salivary glands
- 4.2 Gy
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.